petq-20221109
0001668673false00016686732022-11-092022-11-09


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2022

PETIQ, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)
001-38163
(Commission
File Number)
35-2554312
(I.R.S. Employer
Identification No.)
230 E. Riverside Dr.
Eagle, Idaho
(Address of principal executive offices)
83616
(Zip Code)

(208) 939-8900
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Exchange on Which Registered
Class A common stock, par value $0.001 per sharePETQThe Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act



Item 2.02 Results of Operations and Financial Condition.*

On November 9, 2022, PetIQ, Inc. issued a press release announcing certain financial results for its three and nine months ended September 30, 2022. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit NumberDescription
99.1*
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

*The information furnished under Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


PETIQ, INC.
Dated: November 9, 2022By/s/ Zvi Glasman

Name:Zvi Glasman

Title:
Chief Financial Officer

Document

https://cdn.kscope.io/4ff396f89c86b8e5478944d4e9555fe6-petq-20220504xex99d1001.jpg
PetIQ, Inc. Reports Third Quarter 2022 Financial Results
Third Quarter 2022 Net Sales of Approximately $210 Million at the High-End of Guidance
Adjusted EBITDA Exceeds Company's Third Quarter Guidance
Reports Record Quarterly Cash from Operations of $64.5 Million
Raises 2022 Annual Adjusted EBITDA Outlook

EAGLE, Idaho – November 9, 2022 (GLOBE NEWSWIRE) - PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today reported financial results for the third quarter and nine months ended September 30, 2022.
Cord Christensen, PetIQ’s Chairman & CEO commented, “We are very pleased with our third quarter results. Our team delivered net sales at the high-end of our guidance range for the quarter and we significantly exceeded our adjusted EBITDA outlook, posting strong double-digit growth year-over-year. The third quarter performance was driven by sales growth in five of our seven manufactured product categories, with double-digit growth in four categories. Importantly, third quarter consumption in our flea and tick brands was positive to last year and this result was well ahead of the total category. Our financial results helped us generate the highest amount of cash in a single quarter. Our mission to provide convenient and affordable access to veterinarian products and services has never been more important, pet parents are continuing to see the value we are delivering, and we are increasing our market share as they experience our broad range of pet health and wellness offerings.”
Third Quarter 2022 Highlights Compared to Prior Year Period
Net sales of $209.7 million, the high-end of the Company’s guidance for the quarter of $200 million to $210 million
Product segment net sales of $176.2 million compared to $181.6 million, a decrease of 2.9%; Product segment net sales decreased 1.0% excluding $3.5 million of sales in the prior year period related to loss of distribution rights
Net sales for PetIQ’s manufactured products increased to 32.3% of Product segment net sales compared to 31.0%
Services segment net revenues of $33.5 million compared to $29.0 million, an increase of 15.6%
Gross margin increased 420 basis points to 24.2%; adjusted gross margin increased 290 basis points to 25.8%
Net loss of $49.6 million including a $47.3 million non-cash goodwill impairment charge, compared to a net loss of $8.3 million
Adjusted net income of $4.3 million, or adjusted EPS of $0.15, an increase of 66.7% compared to $2.7 million, or $0.09
EBITDA of $12.8 million, compared to $5.9 million, an increase of 115.8%
Adjusted EBITDA of $19.2 million, compared to $16.4 million, an increase of 17.4% and above the Company's guidance for the quarter of $16.5 million to $17.5 million
Adjusted EBITDA margin increased 140 basis points to 9.2% compared to 7.8%

Nine Month 2022 Highlights Compared to Prior Year Period
Net sales of $737.4 million compared to $735.9 million, slightly above the prior year period; for comparative purposes, net sales increased 5.3% excluding $35.6 million of sales in the prior year period related to loss of distribution rights
Product segment net sales of $643.0 million compared to $654.4 million, a decrease of 1.8%; Product segment net sales increased 3.9% excluding the aforementioned item



Net sales for PetIQ’s manufactured products increased to 29.0% of Product segment net sales compared to 26.9%
Services segment net revenues of $94.5 million compared to $81.4 million, an increase of 16.0%
Gross margin increased 280 basis points to 23.1%; adjusted gross margin increased 230 basis points to 25.0%
Net loss of $41.7 million including a $47.3 million non-cash goodwill impairment charge, compared to a net loss of $1.9 million
Adjusted net income of $36.6 million, or adjusted EPS of $1.25, an increase of 5.0% compared to $33.3 million, or $1.19
EBITDA of $50.0 million, compared to $44.1 million, an increase of 13.4%
Adjusted EBITDA of $78.4 million, compared to $77.6 million, an increase of 1.0%
Adjusted EBITDA margin increased 10 basis points to 10.6% compared to 10.5%



Third Quarter 2022 Financial Results
Net sales were $209.7 million for the third quarter of 2022, at the high-end of the Company’s guidance for the quarter of $200 million to $210 million. Net sales for the third quarter of 2022 decreased 0.4% compared to the prior year period. For comparative purposes, net sales increased 1.3%, excluding $3.5 million of sales in the prior year period related to the previously disclosed loss of distribution rights in the prior year period.
Third quarter Product net sales were in-line with the Company's expectations as it benefited from consumers returning to its core product categories and trading down from more expensive treatments into its PetIQ manufactured brands. The Company's new product launches in 2022 have continued to perform well.

Third quarter 2022 gross profit was $50.8 million, an increase of 20.7%, compared to $42.1 million in the prior year period. Gross margin increased 420 basis points to 24.2% from 20.0% in the prior year period. Adjusted gross profit was $53.0 million, an increase of 14.0%, compared to $46.5 million in the prior year period, reflecting favorable product mix including the success of the Company’s manufactured product portfolio such as the recently launched product NextStar. The Company also benefited from pricing and Services segment optimization during the quarter. Adjusted gross margin increased 290 basis points to 25.8% for the third quarter 2022 compared to 22.9% in the prior year period.

Selling, general and administrative expenses (“SG&A”) was $46.0 million for the third quarter of 2022 compared to $45.3 million in the prior year period. Adjusted SG&A was $41.3 million for the third quarter of 2022 compared to $39.0 million in the prior year period. As a percentage of net sales adjusted SG&A was 21.9%, an increase of 40 basis points compared to the prior year period. A significant driver of the increase in adjusted SG&A expenses was continued marketing investments of $2.1 million to support the growth of PetIQ's manufactured brand product portfolio.
Net loss was $49.6 million for the third quarter of 2022 which includes a $47.3 million non-cash goodwill impairment charge, compared to a net loss of $8.3 million in the prior year period. Adjusted net income for the third quarter of 2022 increased 62.1% to $4.3 million and adjusted earnings per diluted share ("EPS") was $0.15, compared to adjusted net income of $2.7 million, and adjusted EPS of $0.09 in the prior year period.
EBITDA was $12.8 million for the third quarter of 2022 compared to $5.9 million in the prior year period, an increase of 115.8%. Third quarter adjusted EBITDA was $19.2 million, an increase of 17.4%, compared to $16.4 million in the prior year period and above the Company's guidance of $16.5 million to $17.5 million. Adjusted EBITDA margin increased 140 basis points to 9.2% compared to 7.8% in the prior year period.
Adjusted gross profit, adjusted gross margin, adjusted SG&A, adjusted net income (loss), adjusted EPS, adjusted EBITDA, and adjusted EBITDA margin are non-GAAP financial measures. The Company believes these non-GAAP financial measures provide investors with additional insight into the way management views reportable segment operations. See “Non-GAAP Financial Measures” for a definition of these measures and the financial tables that accompany this release for a reconciliation to the most comparable GAAP measure.
Segment Results
Product:
For the third quarter of 2022, Product segment net sales decreased 2.9% to $176.2 million from $181.6 million in the prior year period. For comparative purposes, Product segment net sales decreased 1.0% excluding $3.5 million of sales in the prior year period related to loss of distribution rights, as previously disclosed.

Product segment adjusted EBITDA increased 5.8% to $35.6 million from adjusted EBITDA of $33.7 million in the third quarter of 2021. Product segment adjusted EBITDA margin in the third quarter of 2022 was 20.2% compared to 18.5% in the prior year period as a result of favorable product mix due to sales of PetIQ's manufactured products.



Services:
For the third quarter of 2022, Services segment net revenues were $33.5 million, an increase of 15.6% compared to $29.0 million in the same period last year. Services segment adjusted EBITDA was $4.2 million, an increase of 10.6% compared to $3.8 million in the third quarter of 2021. Services segment net revenues and adjusted EBITDA benefited from improved revenue metrics and optimization of mobile clinics and wellness centers.
Cash Flow and Balance Sheet
The Company ended the quarter with total cash and cash equivalents of $56.7 million. During the third quarter, the Company generated $64.5 million of cash from operations. The Company’s total debt, which is comprised of its term loan, ABL, convertible debt and capital leases, was $454.6 million as of September 30, 2022. The Company had total liquidity, which it defines as cash on hand plus debt availability, of $181.7 million as of September 30, 2022. The Company repurchased a total of $3.9 million, or 373,408 shares, of its Class A Common Stock during the quarter pursuant to its previously announced stock repurchase program.

Outlook
For the full year 2022 the Company expects:
Net sales of $920 million to $940 million, consistent with the net sales guidance previously provided on August 8, 2022. Based on this guidance and solely for comparative purposes, the Company expects net sales to increase 3.7% compared to 2021 based on the mid-point of the guidance and excluding $36.1 million of sales in the prior year related to the loss of distribution rights.

Adjusted EBITDA of $93 million to $95 million, an increase of $1.0 million from the adjusted EBITDA guidance previously provided on August 8, 2022. Based on this guidance and solely comparative purposes, the Company expects adjusted EBITDA to increase approximately 3.2% compared to 2021 based on the mid-point of the guidance and excluding $1.8 million of adjusted EBITDA in the prior year related to the loss of distribution rights.
The Company does not provide guidance for the most directly comparable GAAP measure to Adjusted EBITDA, net income (loss), and similarly cannot provide a reconciliation between its forecasted adjusted EBITDA and net income (loss) without unreasonable effort due to the unavailability of reliable estimates for certain components of net income and the respective reconciliations. These forecasted items are not within the Company’s control, may vary greatly between periods and could significantly impact future financial results for the full year ending December 31, 2022.

Conference Call and Webcast
The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin today at 4:30 p.m. ET. To participate on the live call listeners in North America may dial 844-826-3033 and international listeners may dial 412-317-5185.
In addition, the call will be broadcast live over the Internet hosted at the “Investors” section of the Company's website at www.PetIQ.com. A telephonic playback will be available through November 30, 2022. North American listeners may dial 844-512-2921 and international listeners may dial 412-317-6671; the passcode is 10171940.
About PetIQ
PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. The company engages with customers through more than 60,000 points of distribution across retail and e-commerce channels with its branded and distributed medications, which is further supported by its own world-class medications manufacturing facility in Omaha, Nebraska. The company’s national service platform,



VIP Petcare, operates in over 2,600 retail partner locations in 41 states providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.
Contact: katie.turner@petiq.com or 208.513.1513
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could” and similar expressions. Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances, or achievements expressed or implied by the forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, the impact of COVID-19 on our business and the global economy; changes in general economic or market conditions, including inflation, that could affect overall consumer spending or our industry; our ability to successfully grow our business through acquisitions; our dependency on a limited number of customers; our ability to implement our growth strategy effectively; competition from veterinarians and others in our industry; reputational damage to our brands; economic trends and spending on pets; the effectiveness of our marketing and trade promotion programs; recalls or withdrawals of our products or product liability claims; our ability to manage our manufacturing and supply chain effectively; disruptions in our manufacturing and distribution chains; our ability to introduce new products and improve existing products; our ability to protect our intellectual property; costs associated with governmental regulation; our ability to keep and retain key employees; our ability to sustain profitability; and the risks set forth under the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2021 and other reports filed time to time with the Securities and Exchange Commission. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results. The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Consequently, you should not place undue reliance on forward-looking statements.

Non-GAAP Financial Measures
In addition to financial results reported in accordance with U.S. GAAP, PetIQ uses the following non-GAAP financial measures: adjusted net income (loss), adjusted earnings per share, adjusted gross profit, adjusted gross margin, adjusted SG&A, adjusted EBITDA, and adjusted EBITDA margin.
Adjusted net income (loss) consists of net income (loss) adjusted for tax expense, non-cash goodwill impairment charge, acquisition expenses, integration costs and costs of discontinued clinics, loss on debt extinguishment and related costs, non-same-store adjustment, litigation costs, and stock-based compensation expense. Adjusted net income (loss) is utilized by management to evaluate the effectiveness of our business strategies. Non-GAAP adjusted earnings per share is defined as non-GAAP adjusted net income divided by the weighted average number of shares of common stock outstanding during the period.



Adjusted gross profit consists of gross profit adjusted for gross profit on veterinarian clinics and wellness centers that are not part of same store sales. Adjusted gross profit is utilized by management to evaluate the effectiveness of our business strategies.
Adjusted SG&A consists of SG&A adjusted for acquisition expenses, stock-based compensation expense, non-same store adjustment, loss on debt extinguishment and related costs, integration costs and costs of discontinued clinics, and litigation expense.
EBITDA represents net income before interest, income taxes, depreciation and amortization and a non-cash goodwill impairment charge. Adjusted EBITDA represents EBITDA plus adjustments for transactions that management does not believe are representative of our core ongoing business including acquisition costs, loss on extinguishment of debt, stock-based compensation expense, non-same store adjustment, integration costs and costs of discontinued clinics and litigation expenses. Adjusted EBITDA margin is adjusted EBITDA stated as a percentage of net sales.

Beginning in the fourth quarter and full year ending December 31, 2022, we will no longer add back non-same store adjustments in our calculation of Adjusted EBITDA and will recast prior year period to reflect this change.

Adjusted EBITDA is utilized by management: (i) as a factor in evaluating management's performance when determining incentive compensation, (ii) to evaluate the effectiveness of our business strategies and (iii) allow for improved comparability over prior periods due to significant growth in the Company’s new wellness centers. The Company presents EBITDA because it is a necessary component for computing adjusted EBITDA.
We believe that the use of these non-GAAP measures provides additional tools for investors to use in evaluating ongoing operating results and trends. In addition, you should be aware when evaluating these non-GAAP measures that in the future we may incur expenses similar to those excluded when calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by these or other unusual or non-recurring items. Our computation of non-GAAP measures may not be comparable to other similarly titled measures computed by other companies, because all companies do not calculate these non-GAAP measures in the same manner. Our management does not, and you should not, consider the non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in our financial statements. See a reconciliation of non-GAAP measures to the most comparable GAAP measure, in the financial tables that accompany this release.



PetIQ, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in 000’s except for per share amounts)
September 30, 2022December 31, 2021
Current assets
Cash and cash equivalents$56,718 $79,406 
Accounts receivable, net 125,024 113,947 
Inventories147,049 96,440 
Other current assets7,392 8,896 
Total current assets336,183 298,689 
Property, plant and equipment, net74,823 76,613 
Operating lease right of use assets19,394 20,489 
Other non-current assets1,429 2,024 
Intangible assets, net 176,936 190,662 
Goodwill182,949 231,110 
Total assets$791,714 $819,587 
Liabilities and equity
Current liabilities
Accounts payable$73,399 $55,057 
Accrued wages payable13,795 12,704 
Accrued interest payable2,947 3,811 
Other accrued expenses11,009 11,680 
Current portion of operating leases6,266 6,500 
Current portion of long-term debt and finance leases8,491 8,350 
Total current liabilities115,907 98,102 
Operating leases, less current installments14,005 14,843 
Long-term debt, less current installments444,598 448,470 
Finance leases, less current installments1,481 2,493 
Other non-current liabilities411 459 
Total non-current liabilities460,495 466,265 
Equity
Additional paid-in capital376,277 368,006 
Class A common stock, par value $0.001 per share, 125,000 shares authorized; 29,319 and 29,139 shares issued, respectively29 29 
Class B common stock, par value $0.001 per share, 100,000 shares authorized; 252 and 272 shares issued and outstanding, respectively— — 
Class A treasury stock, at cost, 373 and 0 shares, respectively(3,857)— 
Accumulated deficit(155,898)(114,525)
Accumulated other comprehensive loss(3,138)(684)
Total stockholders' equity213,413 252,826 
Non-controlling interest1,899 2,394 
Total equity215,312 255,220 
Total liabilities and equity$791,714 $819,587 




PetIQ, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, in 000’s, except for per share amounts)
For the Three Months Ended For the Nine Months Ended
September 30, 2022September 30, 2021September 30, 2022September 30, 2021
Product sales$176,217 $181,557 $642,981 $654,448 
Services revenue33,508 28,977 94,453 81,444 
Total net sales209,725 210,534 737,434 735,892 
Cost of products sold131,414 $142,009 485,833 510,673 
Cost of services27,541 $26,453 81,222 75,720 
Total cost of sales158,955 168,462 567,055 586,393 
Gross profit50,770 42,072 170,379 149,499 
Operating expenses
Selling, general and administrative expenses45,984 45,252 144,815 129,066 
Goodwill impairment47,264 — 47,264 — 
Operating (loss) income(42,478)(3,180)(21,700)20,433 
Interest expense, net7,276 6,168 19,696 18,693 
Loss on debt extinguishment— — — 5,453 
Other expense (income), net172 (1,337)(31)(1,992)
Total other expense, net7,448 4,831 19,665 22,154 
Pretax net loss(49,926)(8,011)(41,365)(1,721)
Income tax benefit (expense)355 (317)(368)(187)
Net loss(49,571)(8,328)(41,733)(1,908)
Net loss attributable to non-controlling interest(435)(426)(360)(65)
Net loss attributable to PetIQ, Inc.$(49,136)$(7,902)$(41,373)$(1,843)
Net loss per share attributable to PetIQ, Inc. Class A common stock
Basic$(1.68)$(0.27)$(1.42)$(0.07)
Diluted$(1.68)$(0.27)$(1.42)$(0.07)
Weighted Average shares of Class A common stock outstanding
Basic29,224 28,940 29,224 27,949 
Diluted29,224 28,940 29,224 27,949 



PetIQ, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in 000’s)
For the Nine Months Ended September 30,
20222021
Cash flows from operating activities
Net loss$(41,733)$(1,908)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities
Depreciation and amortization of intangible assets and loan fees26,564 28,936 
Loss on debt extinguishment— 5,453 
Loss (gain) on disposition of property, plant, and equipment56 (1,185)
Stock based compensation expense8,904 7,188 
Goodwill impairment47,264 — 
Other non-cash activity(7)133 
Changes in assets and liabilities
Accounts receivable(11,219)(21,910)
Inventories(50,847)(10,040)
Other assets1,924 (883)
Accounts payable18,957 (4,498)
Accrued wages payable1,083 2,664 
Other accrued expenses(1,818)6,515 
Net cash (used in) provided by operating activities(872)10,465 
Cash flows from investing activities
Proceeds from disposition of property, plant, and equipment— 5,055 
Purchase of property, plant, and equipment(9,797)(24,577)
Net cash used in investing activities(9,797)(19,522)
Cash flows from financing activities
Proceeds from issuance of long-term debt44,000 630,568 
Principal payments on long-term debt(49,700)(595,321)
Repurchase of Class A common stock(3,857)— 
Tax distributions to LLC Owners— (70)
Principal payments on finance lease obligations(1,097)(1,573)
Payment of deferred financing fees and debt discount— (6,454)
Tax withholding payments on Restricted Stock Units(862)(901)
Exercise of options to purchase Class A common stock115 12,617 
Net cash (used in) provided by financing activities(11,401)38,866 
Net change in cash and cash equivalents(22,070)29,809 
Effect of exchange rate changes on cash and cash equivalents(618)(91)
Cash and cash equivalents, beginning of period79,406 33,456 
Cash and cash equivalents, end of period$56,718 $63,174 





PetIQ, Inc.
Summary Segment Results
(Unaudited, in 000’s)

For the Three Months EndedFor the Nine Months Ended
$'s in 000'sSeptember 30, 2022September 30, 2021September 30, 2022September 30, 2021
Products segment sales$176,217 $181,557 $642,981 $654,448 
Services segment revenue:
Same-store sales29,591 21,732 78,580 63,822 
Non same-store sales3,917 7,245 15,873 17,622 
Total services segment revenue$33,508 $28,977 $94,453 $81,444 
Total net sales$209,725 $210,534 $737,434 $735,892 
Adjusted EBITDA
Products$35,634 $33,678 $126,923 $120,657 
Services4,226 3,821 12,050 8,945 
Unallocated Corporate(20,651)(21,135)(60,588)(52,018)
Total Adjusted EBITDA$19,209 $16,364 $78,385 $77,584 


PetIQ, Inc.
Reconciliation between gross profit and adjusted gross profit
(Unaudited, in 000’s)
For the Three Months EndedFor the Nine Months Ended
$'s in 000'sSeptember 30, 2022September 30, 2021September 30, 2022September 30, 2021
Gross profit$50,770 $42,072 $170,379 $149,499 
Plus:
Non same-store gross loss(4)
2,254 4,421 10,158 13,641 
Adjusted gross profit$53,025 $46,493 $180,538 $163,140 
Gross Margin %24.2 %20.0 %23.1 %20.3 %
Adjusted gross margin %25.8 %22.9 %25.0 %22.7 %





PetIQ, Inc.
Reconciliation between Selling, General & Administrative (“SG&A”) and Adjusted SG&A
(Unaudited, in 000’s)


For the Three Months EndedFor the Nine Months Ended
$'s in 000'sSeptember 30, 2022September 30, 2021September 30, 2022September 30, 2021
SG&A$45,984 $45,252 $144,815 $129,066 
Less:
Acquisition costs(2)
1,035 — 1,191 92 
Loss on debt extinguishment and related costs(3)
— — — 985 
Stock based compensation expense2,238 2,627 8,904 7,188 
Non same-store adjustment(4)
1,236 2,334 5,692 5,125 
Integration costs and costs of discontinued clinics(5)
200 (1,041)943 (354)
Litigation expenses— 2,323 3,802 2,886 
Adjusted SG&A$41,275 $39,009 $124,284 $113,144 
% of Sales (GAAP)21.9 %21.5 %19.6 %17.5 %
% of Sales (Adjusted)20.1 %19.2 %17.2 %15.8 %

PetIQ, Inc.
Reconciliation between Net Income and Adjusted EBITDA
(Unaudited, in 000’s)

For the Three Months EndedFor the Nine Months Ended
$'s in 000'sSeptember 30, 2022September 30, 2021September 30, 2022September 30, 2021
Net loss$(49,571)$(8,328)$(41,733)$(1,908)
Plus:
Tax expense (benefit)(355)317 368 187 
Depreciation3,576 3,145 10,773 9,419 
Amortization4,602 4,627 13,602 17,682 
Goodwill impairment(1)
47,264 — 47,264 — 
Interest expense, net7,276 6,168 19,696 18,693 
EBITDA$12,792 $5,929 $49,970 $44,073 
Acquisition costs(2)
1,035 — 1,191 92 
Loss on debt extinguishment and related costs(3)
— — — 6,438 
Stock based compensation expense2,238 2,627 8,904 7,188 
Non same-store adjustment (4)
2,944 6,195 13,575 16,930 
Integration costs and costs of discontinued clinics(5)
200 (1,041)943 (354)
Litigation expenses— 2,323 3,802 2,886 
CFO Transition— 331 — 331 
Adjusted EBITDA$19,209 $16,364 $78,385 $77,584 
Adjusted EBITDA Margin9.2%7.8%10.6%10.5%





PetIQ, Inc.
Reconciliation between Net Income and Adjusted Net Income
(Unaudited, in 000’s, except for per share amounts)

For the Three Months EndedFor the Nine Months Ended
$'s in 000'sSeptember 30, 2022September 30, 2021September 30, 2022September 30, 2021
Net income$(49,571)$(8,328)$(41,733)$(1,908)
Plus:
Tax expense (benefit)(355)317 368 187 
Goodwill impairment(1)
47,264 47,264 
Acquisition costs(2)
1,035 — 1,191 92 
Loss on debt extinguishment and related costs(3)
— — — 6,438 
Stock based compensation expense2,238 2,627 8,904 7,188 
Non same-store adjustment(4)
3,490 6,755 15,850 18,766 
Integration costs and costs of discontinued clinics(5)
200 (1,041)943 (354)
Litigation expenses— 2,323 3,802 2,886 
Adjusted Net income4,301 2,653 $36,589 $33,295 
Non-GAAP adjusted EPS
Basic$0.15 $0.09 $1.25 $1.19 
Diluted$0.15 $0.09 $1.25 $1.19 
Weighted Average shares of Class A common stock outstanding used to compute non-GAAP adjusted EPS
Basic29,224 28,940 29,224 27,949 
Diluted29,224 28,940 29,224 27,949 

(1) Non-cash goodwill impairment due to a significant decline in the Company’s market capitalization, driven primarily by rising interest rates and macroeconomic conditions. Additionally, the Company made the strategic decision to slow expansion plans for the Services business this year.
(2) Acquisition costs include legal, accounting, banking, consulting, diligence, and other costs related to completed and contemplated acquisitions.
(3) Loss on debt extinguishment and related costs are related to our entering into two new credit facilities, including the write off of deferred financing costs and related costs.
(4) Non same-store adjustment includes revenue and costs, and associated gross profit, related to our Services segment wellness centers and host partners with less than six full quarters of operating results, and also include pre-opening expenses.
(5) Integration costs and costs of discontinued clinics represent costs related to integrating the acquired businesses including personnel costs such as severance and signing bonuses, consulting costs, contract termination, and IT conversion costs. Depending on the type of costs, the costs are primarily in the Products and the corporate segments. Costs of discontinued clinics represent costs to close Services segment locations.